Correction: The Board of Directors of Bioretec Ltd resolved on a new stock option plan
Correction: The Board of Directors of Bioretec Ltd resolved on a new stock option plan
Bioretec Ltd Company Announcement 7 July 2026 at 6:55 p.m. EEST
Bioretec Ltd corrects its release concerning the decisions of its Board of Directors on a new stock option plan on 1 June 2026 at 7.05 p.m. EEST. The split between the stock options marked with the symbol 2026A and 2026B was incorrect.
Incorrect information:
Number of stock options marked with the symbol 2026A: 96,059,674
Number of stock options marked with the symbol 2026B: 86,911,133
Correct information:
Number of stock options marked with the symbol 2026A: 97,584,430
Number of stock options marked with the symbol 2026B: 85,386,377
Otherwise, the content of the release remains unchanged, and the corrected release is presented in full below:
The Board of Directors of Bioretec ltd resolved on a new stock option plan
The Board of Directors of Bioretec Ltd has resolved to establish a new stock option plan for key personnel and selected consultants of the Group. There is a weighty financial reason for the Company to issue stock options, as they are intended to form part of the incentive and commitment program for the Group’s key personnel and consultants. The stock options are intended to encourage the participants to work on a long-term basis to increase shareholder value and to commit the participants to the service of the Company. The stock option plan is directed to approximately 30 key persons and consultants.
A maximum total of 182,970,807 stock options will be issued, entitling their owners to subscribe for a maximum total of 182,970,807 new shares in the Company or existing shares held by the Company. The stock options are issued gratuitously. Of the stock options, 97,584,430 are marked with the symbol 2026A and 85,386,377 are marked with the symbol 2026B.
The shares to be subscribed for on the basis of the issued stock options correspond to a maximum total of 12 per cent of all the shares and votes in the Company after potential share subscriptions, should new shares be issued in the subscription. As a result of the share subscriptions, the number of shares in the Company may increase by a maximum total of 182,970,807 shares, should new shares be issued in the subscription.
The stock options vest gradually over four years, subject to continued employment or service. After a 12-month cliff, 40 per cent of the 2026A options and 25 per cent of the 2026B options will vest. The remaining options of both classes will vest in equal quarterly instalments over the subsequent three years.
The share subscription price for stock options 2026A and 2026B is the volume-weighted average share price (VWAP) of the Company’s share during the period of one (1) month commencing on April 29, 2026, plus a 20 per cent premium.
The share subscription price will be credited to the reserve for the Company’s invested unrestricted equity. The share subscription price will be reduced by the amount of dividends and assets from reserves of unrestricted equity per share resolved after the Board’s resolution but before the share subscription.
The share subscription period for the stock options starts when options vest and ends on May 31, 2032, for both stock options 2026A and 2026B.
The theoretical market value of one stock option is EUR 0.0172 per stock option. The total theoretical market value of all stock options is approximately EUR 3,147,098. The theoretical market value of one stock option has been calculated using the Black & Scholes stock option pricing model, taking into account the exercise price of the stock option and the following assumptions: share price EUR 0.0226, risk-free interest rate 2.77%, time to maturity approximately six years, current dividend yield 0% and volatility approximately 89.60%.
The Board of Directors resolved on the new stock option plan by virtue of an authorisation granted by the Extraordinary General Meeting of Shareholders on March 27, 2026.
Contacts
Kustaa Poutiainen, Chairperson of the Board, +358 40 042 4506
Certified adviser
Nordic Certified Adviser AB, +46 70 551 67 29
Information about Bioretec
Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.
The company’s latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.
Bioretec’s Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients.
Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.
To learn more about Bioretec, visit www.bioretec.com
Inside information: Chief Financial Officer Tuukka Paavola will leave the company
Inside information: Chief Financial Officer Tuukka Paavola will leave the company
Bioretec Ltd, Inside Information, 2 July 2026 at 14.30 EEST
Bioretec Ltd and Tuukka Paavola have mutually agreed that Paavola will not continue in his position. Paavola will leave his role with immediate effect. The duties of the Chief Financial Officer will be assumed on an interim basis by Controller Anna-Mari Venola until a new Chief Financial Officer is appointed.
Bioretec will immediately initiate the recruitment process for a new Chief Financial Officer.
Paavola started in the position on January 20, 2026.
Bioretec thanks Tuukka Paavola for his contribution as Chief Financial Officer and wishes him success in his future endeavors.
Further enquiries
Sarah van Hellenberg Hubar-Fisher, CEO, +31 6 1544 8736
Certified adviser
Nordic Certified Adviser AB, +46 70 551 67 29
Information about Bioretec
Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.
The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.
Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients.
Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.
To learn more about Bioretec, visit www.bioretec.com
Bioretec appoints Conan Cavanagh as Head of Research & Development and member of the Management Team
Bioretec appoints Conan Cavanagh as Head of Research & Development and member of the Management Team
Bioretec Ltd | Press Release | 17 June 2026 at 16:00 EEST
Bioretec Ltd, a pioneer in absorbable orthopedic implants, has appointed Conan Cavanagh as Head of Research & Development and as a member of the management team as of 1 September 2026. Cavanagh will report directly to CEO Sarah van Hellenberg Hubar-Fisher.
Conan Cavanagh has over 25 years of experience in the development of medical devices, biomaterials, and product commercialization. He currently serves as Chief Operating Officer and Head of Research & Development at HidraMed Solutions. Previously, among other positions, he has served as Engineering Director at Smith & Nephew, where he was broadly responsible for the development and commercialization of orthopedic and sports medicine products.
Cavanagh has a bachelor’s degree in biomedical engineering and also holds a master’s degree in management. He has extensive experience across the full lifecycle of product development, from concept generation to commercialization. In addition, he has deep expertise in clinical studies, regulatory processes and intellectual property management.
In his new role at Bioretec, Cavanagh will be responsible for the company’s research and development strategy, management of the product portfolio, and the execution of the product development program. He will have a central role in strengthening Bioretec’s technological development, clinical evidence and regulatory readiness, as well as in supporting the company’s long-term growth and international competitiveness.
“I am very pleased to be joining Bioretec’s team at this important stage and to have the opportunity to advance the company’s growth through innovation and new technology,” says Conan Cavanagh.
“We are thrilled to welcome Conan Cavanagh to Bioretec. We look forward to his leadership and input as we continue on our mission to become the global market leader in absorbable orthopedic implants. Conan joins us at a pivotal and exciting stage in the company’s development, and we are excited to see his significant contribution to executing our strategy, advancing our technology and supporting our international growth,” says CEO Sarah van Hellenberg Hubar-Fisher.
Further enquiries
Sarah van Hellenberg Hubar-Fisher, CEO, +31 6 1544 8736
Certified adviser
Nordic Certified Adviser AB, +46 70 551 67 29
Information about Bioretec
Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.
The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.
Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients.
Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.
To learn more about Bioretec, visit www.bioretec.com
Bioretec appoints Conan Cavanagh as Head of Research & Development and member of the Management Team
Bioretec appoints Conan Cavanagh as Head of Research & Development and member of the Management Team
Bioretec Ltd | Press Release | 17 June 2026 at 16:00 EEST
Bioretec Ltd, a pioneer in absorbable orthopedic implants, has appointed Conan Cavanagh as Head of Research & Development and as a member of the management team as of 1 September 2026. Cavanagh will report directly to CEO Sarah van Hellenberg Hubar-Fisher.
Conan Cavanagh has over 25 years of experience in the development of medical devices, biomaterials, and product commercialization. He currently serves as Chief Operating Officer and Head of Research & Development at HidraMed Solutions. Previously, among other positions, he has served as Engineering Director at Smith & Nephew, where he was broadly responsible for the development and commercialization of orthopedic and sports medicine products.
Cavanagh has a bachelor’s degree in biomedical engineering and also holds a master’s degree in management. He has extensive experience across the full lifecycle of product development, from concept generation to commercialization. In addition, he has deep expertise in clinical studies, regulatory processes and intellectual property management.
In his new role at Bioretec, Cavanagh will be responsible for the company’s research and development strategy, management of the product portfolio, and the execution of the product development program. He will have a central role in strengthening Bioretec’s technological development, clinical evidence and regulatory readiness, as well as in supporting the company’s long-term growth and international competitiveness.
“I am very pleased to be joining Bioretec’s team at this important stage and to have the opportunity to advance the company’s growth through innovation and new technology,” says Conan Cavanagh.
“We are thrilled to welcome Conan Cavanagh to Bioretec. We look forward to his leadership and input as we continue on our mission to become the global market leader in absorbable orthopedic implants. Conan joins us at a pivotal and exciting stage in the company’s development, and we are excited to see his significant contribution to executing our strategy, advancing our technology and supporting our international growth,” says CEO Sarah van Hellenberg Hubar-Fisher.
Further enquiries
Sarah van Hellenberg Hubar-Fisher, CEO, +31 6 1544 8736
Certified adviser
Nordic Certified Adviser AB, +46 70 551 67 29
Information about Bioretec
Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.
The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.
Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients.
Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.
To learn more about Bioretec, visit www.bioretec.com
Bioretec concludes change negotiations
Bioretec concludes change negotiations
Bioretec Ltd, Press Release, 17 June 2026 at 9:00 EEST
On 1 June 2026, Bioretec announced the initiation of change negotiations in accordance with the Finnish Act on Co-operation within Undertakings, focusing on the company’s production function in Finland. The aim of the negotiations was to streamline operations and consequently to improve the company’s competitiveness and profitability.
The negotiations began on 8 June 2026 and were concluded today.
At the start of the negotiations, the company estimated that the plans may impact the terms of employment of up to four individuals in Finland. As a result of the negotiations, the employment of three employees will be terminated.
A total of 12 employees from Bioretec’s staff in Finland were included in the scope of the negotiations.
Further enquiries
Tuukka Paavola, CFO, +358 50 386 0013
Information about Bioretec
Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.
The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.
Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients.
Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.
To learn more about Bioretec, visit www.bioretec.com
Bioretec Ltd – Manager’s transactions – van Hellenberg Hubar-Fisher
Bioretec Ltd – Manager’s transactions – van Hellenberg Hubar-Fisher
Bioretec Ltd Company release 4 June 2026 at 14:25 p.m. EEST
Bioretec Ltd - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Sarah van Hellenberg Hubar-Fisher
Position: Chief Executive Officer
Issuer: Bioretec Oy
LEI: 7437008736AG7HY51K13
Notification type: INITIAL NOTIFICATION
Reference number: 159307/6/8
____________________________________________
Transaction date: 2026-06-02
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)
Instrument type: SHARE
ISIN: FI4000480454
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 1660000 Unit price: 0.02258 EUR
Aggregated transactions (1):
Volume: 1660000 Volume weighted average price: 0.02258 EUR
Further enquiries
Tuukka Paavola, CFO, +358 50 386 0013
Certified adviser
Nordic Certified Adviser AB, +46 70 551 67 29
Information about Bioretec
Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.
The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.
Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients.
Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.
To learn more about Bioretec, visit www.bioretec.com
Bioretec Ltd – Manager’s transactions – Jordy Winters
Bioretec Ltd – Manager’s transactions – Jordy Winters
Bioretec Oy Company release 2 June 2026 at 13:25 p.m. EEST
Bioretec Oy - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Jordy Winters
Position: Other senior manager
Issuer: Bioretec Oy
LEI: 7437008736AG7HY51K13
Notification type: INITIAL NOTIFICATION
Reference number: 158959/6/4
____________________________________________
Transaction date: 2026-05-29
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)
Instrument type: SHARE
ISIN: FI4000480454
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 50000 Unit price: 0.0224 EUR
(2): Volume: 109000 Unit price: 0.0224 EUR
(3): Volume: 82596 Unit price: 0.0224 EUR
(4): Volume: 2849 Unit price: 0.0224 EUR
(5): Volume: 200000 Unit price: 0.0224 EUR
(6): Volume: 555555 Unit price: 0.0224 EUR
Aggregated transactions (6):
Volume: 1000000 Volume weighted average price: 0.0224 EUR
Further enquiries
Tuukka Paavola, CFO, +358 50 386 0013
Certified adviser
Nordic Certified Adviser AB, +46 70 551 67 29
Information about Bioretec
Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.
The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.
Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients.
Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.
To learn more about Bioretec, visit www.bioretec.com
The Board of Directors of Bioretec Ltd resolved on a new stock option plan
The Board of Directors of Bioretec Ltd resolved on a new stock option plan
Bioretec Ltd Company Announcement 1 June 2026 at 19:05 p.m. EEST
THE BOARD OF DIRECTORS OF BIORETEC LTD RESOLVED ON A NEW STOCK OPTION PLAN
The Board of Directors of Bioretec Ltd has resolved to establish a new stock option plan for key personnel and selected consultants of the Group. There is a weighty financial reason for the Company to issue stock options, as they are intended to form part of the incentive and commitment program for the Group's key personnel and consultants. The stock options are intended to encourage the participants to work on a long-term basis to increase shareholder value and to commit the participants to the service of the Company. The stock option plan is directed to approximately 30 key persons and consultants.
A maximum total of 182,970,807 stock options will be issued, entitling their owners to subscribe for a maximum total of 182,970,807 new shares in the Company or existing shares held by the Company. The stock options are issued gratuitously. Of the stock options, 96,059,674 are marked with the symbol 2026A and 86,911,133 are marked with the symbol 2026B.
The shares to be subscribed for on the basis of the issued stock options correspond to a maximum total of 12 per cent of all the shares and votes in the Company after potential share subscriptions, should new shares be issued in the subscription. As a result of the share subscriptions, the number of shares in the Company may increase by a maximum total of 182,970,807 shares, should new shares be issued in the subscription.
The stock options vest gradually over four years, subject to continued employment or service. After a 12-month cliff, 40 per cent of the 2026A options and 25 per cent of the 2026B options will vest. The remaining options of both classes will vest in equal quarterly instalments over the subsequent three years.
The share subscription price for stock options 2026A and 2026B is the volume-weighted average share price (VWAP) of the Company's share during the period of one (1) month commencing on April 29, 2026, plus a 20 per cent premium.
The share subscription price will be credited to the reserve for the Company's invested unrestricted equity. The share subscription price will be reduced by the amount of dividends and assets from reserves of unrestricted equity per share resolved after the Board’s resolution but before the share subscription.
The share subscription period for the stock options starts when options vest and ends on May 31, 2032, for both stock options 2026A and 2026B.
The theoretical market value of one stock option is EUR 0.0172 per stock option. The total theoretical market value of all stock options is approximately EUR 3,147,098. The theoretical market value of one stock option has been calculated using the Black & Scholes stock option pricing model, taking into account the exercise price of the stock option and the following assumptions: share price EUR 0.0226, risk-free interest rate 2.77%, time to maturity approximately six years, current dividend yield 0% and volatility approximately 89.60%.
The Board of Directors resolved on the new stock option plan by virtue of an authorisation granted by the Extraordinary General Meeting of Shareholders on March 27, 2026.
Contacts
Kustaa Poutiainen, Chairperson of the Board, +358 40 042 4506
Certified adviser
Nordic Certified Adviser AB, +46 70 551 67 29
Information about Bioretec
Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.
The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.
Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients.
Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.
To learn more about Bioretec, visit www.bioretec.com
Inside information: Bioretec initiates new change negotiations in production to enhance operational efficiency
Inside information: Bioretec initiates new change negotiations in production to enhance operational efficiency
Inside information: Bioretec initiates new change negotiations in production to enhance operational efficiency
Bioretec Ltd — Inside information — 1 June 2026 at 19:00 EEST
Bioretec Ltd initiates change negotiations in accordance with the Finnish Act on Co-operation within Undertakings. The aim of the negotiations is to streamline operations and consequently to improve the company’s competitiveness and profitability. The negotiations will focus on Bioretec’s production function in Finland.
The change negotiations will commence on 8 June 2026 and are estimated to last for approximately two weeks.
A total of 12 employees from Bioretec’s staff in Finland are included in the scope of the negotiations. The negotiations may impact the employment terms of up to four individuals. Potential measures under negotiation may include terminations of employment. The objective of the negotiations is to achieve estimated annual cost savings of approximately EUR 0.2 million, separate from the EUR 0.4 million cost savings target communicated in connection with the previous change negotiations.
As the company communicated on 12 November 2025, Bioretec’s investments in production have proven to be oversized in relation to the realized business development. Bioretec underwent change negotiations concerning its production function in November 2025, resulting in the termination of one production employee and the temporary layoff of five employees. Based on the company’s assessment, the measures implemented thus far are not sufficient on their own to adapt production to the current business volumes. Consequently, the company considers additional measures necessary to further adjust its cost structure.
Bioretec will keep its personnel informed about the progress of the negotiations and will publicly announce the outcome once the negotiations have concluded.
Further enquiries
Tuukka Paavola, CFO, +358 50 386 0013
Certified adviser
Nordic Certified Adviser AB, +46 70 551 67 29
Information about Bioretec
Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.
The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.
Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients.
Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.
To learn more about Bioretec, visit www.bioretec.com
Bioretec Ltd - Managers' transactions - Paavola
Bioretec Ltd - Managers' transactions - Paavola
Bioretec Ltd Company Release 18 May 2026 at 1:45 p.m. EEST
Bioretec Oy - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Tuukka Paavola
Position: Chief Financial Officer
Issuer: Bioretec Oy
LEI: 7437008736AG7HY51K13
Notification type: INITIAL NOTIFICATION
Reference number: 157184/4/4
____________________________________________
Transaction date: 2026-05-18
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)
Instrument type: SHARE
ISIN: FI4000480454
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 500000 Unit price: 0.0198 EUR
Aggregated transactions (1):
Volume: 500000 Volume weighted average price: 0.0198 EUR
Further enquiries
Tuukka Paavola, CFO, +358 50 386 0013
Certified adviser
Nordic Certified Adviser AB, +46 70 551 67 29
Information about Bioretec
Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.
The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.
Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients.
Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.
To learn more about Bioretec, visit www.bioretec.com